Theralase Technologies (TLT) AI Stock Analysis

• Market Cap: C$47.08M
• Dividend Yield: N/A
• Average Volume (3M): 97.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.24
• Revenue Growth: -3.45%
• EPS Growth: 12.98%
• Country: CA
• Employees: 14
• Sector: Technology
• Sector Strength: 62
• Industry: Medical - Devices
• EPS (TTM): -0.02
• Shares Outstanding: 247,780,360
• 10 Day Avg. Volume: 43,985
• 30 Day Avg. Volume: 97,633
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 45.15
• Price to Cash Flow (P/CF): -25.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Theralase Technologies faces severe financial difficulties, including declining revenues and persistent losses, which weigh heavily on the stock score. Technical indicators and valuation metrics further contribute to a weak outlook. While there are some promising developments in clinical research, these are overshadowed by fundamental financial and operational challenges.

Theralase Technologies Business Overview & Revenue Model

Company Description

Theralase Technologies Inc. is a Canadian company operating in the biotechnology and medical device sectors. The company specializes in the design, development, and manufacturing of laser-based technologies aimed at providing advanced therapeutic solutions. Its core products include laser systems used in the treatment of pain and inflammation as well as in the destruction of cancer cells. Theralase's innovative technologies are utilized in various healthcare settings, offering non-invasive solutions to complex medical challenges.

How the Company Makes Money

Theralase Technologies generates revenue primarily through the sale of its laser therapy systems and related consumables. The company's revenue streams include direct sales to healthcare providers, distributors, and clinics that utilize its products for pain management and cancer treatment. Additionally, Theralase may engage in licensing agreements or partnerships that expand the reach and application of its technologies, potentially providing additional income sources. The company invests in research and development to enhance its product offerings, which can also lead to increased market penetration and revenue growth over time.

Theralase Technologies Financial Statement Overview

Summary

Theralase Technologies faces significant financial challenges, characterized by decreasing revenues, persistent losses, and negative cash flows. While the company maintains low leverage, the reliance on external financing and negative profitability metrics indicate a need for strategic improvements to ensure long-term viability.

Income Statement

Theralase Technologies has been experiencing declining revenue over the past few years, with a notable decrease from $1,138,569 in 2022 to $1,033,431 in 2024. The company has consistently reported negative net income, indicating ongoing losses. Gross profit margins have been low and deteriorating, reflecting challenges in cost management. The negative EBITDA and EBIT margins further highlight operational inefficiencies and lack of profitability.

Balance Sheet

The balance sheet shows a weakening position, with declining total assets and stockholders' equity over the years. The debt-to-equity ratio remains low due to minimal debt, which is a positive aspect. However, the equity ratio is declining, and the return on equity is negative due to continued losses, presenting a risk to financial stability.

Cash Flow

Theralase Technologies has been consistently generating negative operating cash flow and free cash flow, indicating struggles with generating cash from core operations. Free cash flow has shown some improvement in recent years but remains negative, highlighting cash management issues. Financing activities have been the primary source of cash, which could pose a risk if external funding becomes limited.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.03M	1.07M	1.14M	780.64K	929.12K
	Gross Profit
554.03K	562.13K	628.17K	309.94K	269.68K
	EBIT
0.00	-4.59M	-5.20M	-4.52M	-5.59M
	EBITDA
-3.96M	-4.25M	-4.90M	-4.31M	-5.56M
	Net Income Common Stockholders
-4.26M	-4.57M	-5.25M	-4.42M	-5.61M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
268.76K	43.91K	1.51M	3.69M	7.88M
	Total Assets
3.25M	3.28M	4.16M	5.94M	10.02M
	Total Debt
293.87K	386.88K	473.62K	35.72K	92.34K
	Net Debt
25.11K	342.97K	-1.03M	-3.66M	-7.79M
	Total Liabilities
1.18M	1.37M	1.07M	874.79K	857.13K
	Stockholders Equity
2.07M	1.91M	3.09M	5.07M	9.16M
Cash Flow		Free Cash Flow
-3.35M	-4.11M	-5.20M	-4.13M	-4.61M
	Operating Cash Flow
-3.33M	-4.07M	-5.13M	-4.03M	-4.45M
	Investing Cash Flow
-19.97K	-37.27K	-70.41K	-100.82K	-164.58K
	Financing Cash Flow
3.57M	2.65M	3.02M	-57.37K	-57.56K

Theralase Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TLT, the sentiment is Negative. The current price of 0.19 is below the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.22, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.37 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TLT.

Theralase Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	59 Neutral	$10.72B	10.22	-6.67%	3.02%	7.42%	-11.38%
VPT	44 Neutral	C$22.83M	―	207.08%	―	280.56%	-7.28%
TLT	42 Neutral	C$47.08M	―	-214.26%	―	-3.45%	12.98%
BCT	41 Neutral	C$26.93M	―	-478.64%	―	―	56.78%
SVA	33 Underperform	C$62.41M	―	248.46%	―	―	32.71%

Theralase Technologies Corporate Events

Theralase Technologies Secures $CAN 419,124 in Private Placement to Boost Cancer and Virus Research

Theralase Technologies Inc. has successfully closed a non-brokered private placement, raising $CAN 419,124 through the issuance of 1,995,829 units. The proceeds will be used to advance their Phase II clinical study on Non-Muscle Invasive Bladder Cancer, research on Herpes Simplex Virus treatment, and development of Rutherrin® for various solid-core tumors. This financing move is expected to bolster the company’s ongoing research and development efforts, potentially enhancing its position in the pharmaceutical industry.

Spark’s Take on TSE:TLT Stock

According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.

Theralase Technologies’ overall stock score reflects financial struggles with declining revenues and persistent losses. While recent clinical advancements and corporate events are promising, these are overshadowed by ongoing financial and fundraising challenges. The stock’s technical indicators and valuation metrics further highlight its current unattractiveness in the market.

To see Spark’s full report on TSE:TLT stock, click here.

Theralase’s Ruvidar Outperforms Standard Herpes Treatments in Preclinical Trials

Theralase Technologies has announced that its product, Ruvidar, has demonstrated higher efficacy in treating Herpes Simplex Virus, Type 1 (HSV-1) compared to FDA-approved treatments Acyclovir and Abreva in a preclinical animal model. The research showed that Ruvidar, applied once daily, was able to completely heal HSV-1 lesions, unlike the other treatments which required more frequent applications and higher doses. This promising result suggests a potential advancement in HSV-1 treatment, with implications for further clinical studies and possible market introduction.

Spark’s Take on TSE:TLT Stock

According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.

Theralase Technologies faces significant financial struggles, including declining revenues and persistent losses. While there are promising developments in clinical research and strategic initiatives, the stock’s valuation and technical indicators remain unattractive. Earnings call insights and recent corporate events offer some positive prospects but are overshadowed by fundamental financial challenges.

To see Spark’s full report on TSE:TLT stock, click here.

Theralase Achieves 7-Year Cancer Remission with Ruvidar Treatment

Theralase Technologies has announced a significant milestone in its Phase Ib clinical study for Non-Muscle Invasive Bladder Cancer (NMIBC). A patient treated with their light-activated small molecule Ruvidar demonstrated a complete response lasting over seven years, highlighting the potential of Ruvidar in treating BCG-unresponsive NMIBC Carcinoma In-Situ. This development underscores the effectiveness of Theralase’s approach in addressing challenging cancer types and positions the company for further clinical advancements and regulatory submissions.

Spark’s Take on TSE:TLT Stock

According to Spark, TipRanks’ AI Analyst, (TSE:TLT) is a Neutral.

Theralase Technologies’ stock score reflects significant financial struggles, including declining revenues and persistent losses, alongside bearish technical indicators. Despite some positive developments in clinical research and strategic initiatives, the company’s valuation remains unattractive. Earnings call insights provide a mixed outlook, with challenges in fundraising and increasing operational costs weighing heavily on the stock’s potential performance.

To see Spark’s full report on (TSE:TLT) stock, click here.

Theralase Technologies Releases 2024 Financial Statements

Theralase Technologies has released its audited consolidated financial statements for the year ending December 31, 2024. The company will hold a conference call on March 19, 2025, to discuss the financial and operational results, providing stakeholders with insights into its performance and future prospects.

Theralase Technologies Secures $CAN 310,200 in Private Placement to Boost Cancer Research

Theralase Technologies Inc. has successfully closed a non-brokered private placement, raising approximately $CAN 310,200 through the issuance of 1,034,002 units. The funds will be used to advance their Phase II Non-Muscle Invasive Bladder Cancer clinical study, preclinical research and development of Rutherrin®, and for general corporate purposes. This move is expected to strengthen the company’s operational capabilities and support its ongoing research efforts, potentially enhancing its position in the pharmaceutical industry.

Theralase’s Cool Laser Therapy Shows Promise in Parkinson’s Treatment

Theralase Technologies has announced promising interim clinical data showing that their TLC-2400 Cool Laser Therapy system improves motor and non-motor functions in patients with Parkinson’s Disease. This development could significantly impact the treatment landscape for Parkinson’s, a prevalent neurodegenerative disorder, by offering a non-invasive option that enhances neuromotor function through dopamine production.

Theralase’s Rutherrin Shows Promise in Non-Hodgkin’s Lymphoma Treatment

Theralase Technologies announced that its lead compound, Rutherrin, has shown efficacy in destroying Non-Hodgkin’s Lymphoma in an animal model when combined with Metformin and radiation. This development could potentially impact the company’s operations by enhancing its position in the oncology market, particularly in the treatment of Non-Hodgkin’s Lymphoma, which is a significant global health concern with a large market potential.

Theralase Validates Effective Treatment for Herpes Virus

Theralase Technologies has announced the successful validation of previous research from the University of Manitoba, demonstrating that Ruvidar is safe and effective in treating the Herpes Simplex Virus, Type 1 (HSV-1) in animal models. This announcement is significant given the global prevalence of HSV-1, which affects an estimated 3.8 billion people under age 50, and the growing HSV treatment market, projected to expand due to increasing concerns over the infection’s spread.

Theralase’s Ruvidar Proves Superior to Acyclovir in HSV Treatment

Theralase Technologies has announced that independent research by the University of Manitoba has verified that Ruvidar, a small molecule developed by the company, is significantly more effective than acyclovir in inactivating Herpes Simplex Viruses post-infection. This finding could have significant implications for the treatment of herpes simplex viruses, as Ruvidar was shown to inhibit viral replication at lower concentrations and demonstrated additive and synergistic effects in combination therapy.

Theralase’s Innovative Bladder Cancer Treatment to be Highlighted at AUA Annual Meeting

Theralase Technologies announced that its interim clinical data on the light-activated Ruvidar™ for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ will be presented at the 2025 American Urological Association Annual Meeting. This data highlights the treatment’s safety and efficacy, offering a potential significant advancement in bladder cancer therapy for patients with limited options. The treatment has shown promising results, with some patients experiencing a durable response of three years or more, potentially revolutionizing the treatment landscape for bladder cancer and allowing patients to avoid radical cystectomy.